OptimizeRx (OPRX) Stock Price, News & Analysis

Company Overview

OptimizeRx Corporation is a digital health company that provides technology and communication solutions for the life sciences and healthcare industries. Its platform connects pharmaceutical and biotechnology companies with healthcare providers and patients through digital channels integrated into electronic health records, electronic prescribing systems and other clinical workflows.

The company’s solutions support activities such as delivering treatment information, patient savings and affordability offers, medication adherence programs, and other communications intended to help patients access and remain on prescribed therapies. OptimizeRx also provides tools designed to help life sciences companies engage healthcare professionals, support product education and generate insights from healthcare data.

Founded in 2006, OptimizeRx has primarily served the U.S. healthcare market, working with pharmaceutical manufacturers, biotechnology companies, healthcare providers and technology partners. The company is headquartered in Michigan and has historically been led by co-founder and Chief Executive Officer William J. Febbo.

Key Stats

• Today's Range: $8.45 to $8.79
• 50-Day Range: $6.05 to $8.78
• 52-Week Range: $4.54 to $22.25
• Volume: 166,707 shs
• Average Volume: 157,122 shs
• Market Capitalization: $166.32 million
• P/E Ratio: 38.41
• Dividend Yield: N/A
• Price Target: $11.57
• Consensus Rating: Moderate Buy

OptimizeRx Stock Analysis - MarketRank™

OptimizeRx scored higher than 87% of companies evaluated by MarketBeat, and ranked 55th out of 885 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

OptimizeRx has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on no strong buy ratings, 6 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

OptimizeRx has a consensus price target of $11.57, representing about 32.7% upside from its current price of $8.72.

Amount of Analyst Coverage

OptimizeRx has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 34.69%

Earnings Growth

Earnings for OptimizeRx are expected to grow by 34.69% in the coming year, from $0.49 to $0.66 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of OptimizeRx is 37.91, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.66.

Price to Earnings Ratio vs. Sector

The P/E ratio of OptimizeRx is 37.91, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.34.

Price to Book Value per Share Ratio

OptimizeRx has a P/B Ratio of 1.27. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

5.79% of the float of OptimizeRx has been sold short.

Short Interest Ratio / Days to Cover

OptimizeRx has a short interest ratio ("days to cover") of 9.31.

Change versus previous month

Short interest in OptimizeRx has recently decreased by 13.14%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

OptimizeRx does not currently pay a dividend.

Dividend Growth

OptimizeRx does not have a long track record of dividend growth.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.32

News Sentiment

OptimizeRx has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for OptimizeRx this week, compared to 2 articles on an average week.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, OptimizeRx insiders have not sold or bought any company stock.

Percentage Held by Insiders

7.50% of the stock of OptimizeRx is held by insiders.

Percentage Held by Institutions

76.47% of the stock of OptimizeRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 10/06/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Technology
• Sub-Industry: Healthcare Technology
• Current Symbol: NASDAQ:OPRX
• CIK: 1448431
• Web: www.optimizerx.com
• Phone: (248) 651-6568
• Fax: 248-453-5529
• Employees: 105
• Year Founded: 2006

Price Target and Rating

• Average Price Target for OptimizeRx: $11.57
• High Price Target: $18.00
• Low Price Target: $7.00
• Potential Upside/Downside: +31.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.56
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.23
• Trailing P/E Ratio: 38.41
• Forward P/E Ratio: 18.02
• P/E Growth: N/A
• Net Income: $5.13 million
• Net Margins: 4.66%
• Pretax Margin: 6.84%
• Return on Equity: 9.44%
• Return on Assets: 7.11%

Debt

• Debt-to-Equity Ratio: 0.14
• Current Ratio: 5.58
• Quick Ratio: 5.58

Sales & Book Value

• Annual Sales: $98.65 million
• Price / Sales: 1.69
• Cash Flow: $1.01 per share
• Price / Cash Flow: 8.71
• Book Value: $6.88 per share
• Price / Book: 1.28

Miscellaneous

• Outstanding Shares: 18,836,000
• Free Float: 17,423,000
• Market Cap: $166.34 million
• Optionable: Optionable
• Beta: 1.26